ABOS - CIK 0001576885
The table below shows Acumen Pharmaceuticals, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $16.48M | $21.97M | $37.13M | $25.27M | $27.25M | $19.53M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $4.67M |
| $4.54M |
| $4.63M |
| $5.10M |
| $5.02M |
| $4.85M |
| Operating income | -$21.15M | -$26.51M | -$41.75M | -$30.37M | -$32.27M | -$24.38M |
| Income tax | - | - | - | - | - | - |
| Net income | -$20.74M | -$26.45M | -$40.95M | -$28.80M | -$29.77M | -$20.54M |
| EPS (diluted) | -$0.33 | -$0.44 | -$0.68 | -$0.48 | -$0.50 | -$0.34 |